What UMED Inc. does

UMED Inc. (유메드) is a South Korea-based urologic healthcare platform founded in 2020 by Professor Park Myung-chan, a practicing urologist at Inje University Haeundae Paik Hospital. The company develops precision medical devices targeting catheter-associated urinary tract infections (CAUTI) and underserved urology patient populations, particularly the 80% of catheter patients who do not currently receive adequate bladder irrigation treatment. Its core product, UroRinse™ Light, is positioned as the world's first fully automated bladder irrigation system, using multi-sensor control technology to automate fluid inflow and outflow within a closed-system design that minimizes contamination risk. A secondary product line, UroAll® Solution, addresses urethral and bladder management through drug-eluting catheter technology developed in partnership with BioPlus.

The company's technology stack integrates the hardware devices with a connected digital health ecosystem spanning mobile applications, cloud databases, an AI-powered medical information chatbot, and symptom-analysis-based referral services. A September 2025 MOU with People & Technology extends this ecosystem via IoMT integration with the IndoorPlus+ SmartCare hospital platform, targeting EMR/HIS connectivity by 2027. UMED has secured Korean medical device manufacturing certification for UroRinse Light as of October 28, 2025, and is pursuing FDA and CE clearance for international expansion. Preclinical validation was published in the journal Urology (Gold Journal) in July 2025 through a collaboration with UCSD.

The business model centers on direct hardware sales to Korean hospitals and nursing facilities, with planned expansion into home care channels and future recurring revenue from digital platform subscriptions and AI-powered infection prevention services. GTM is primarily enterprise field sales to major Korean hospital groups including Asan Medical Center, Seoul National University Hospital, and several university hospitals, supported by participation in CES 2026 and acceleration programs (IBK창공, BTV Ventures). The company is venture-backed, with disclosed investors including Series Ventures, BTV Ventures, Widen Partners, Dream Ventures, and Busan United Holdings, alongside government grants. UMED operates from headquarters in Gimhae with additional offices in Busan and Ulsan, and currently has 1-10 employees.

Name

UMED Inc.

Legal name

(주)유메드

Website

https://umedglobal.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

UMED Inc. is a South Korean urologic healthcare platform that has developed UroRinse™ Light, the world's first automated bladder irrigation system, targeting catheter-associated urinary tract infections. The company sells its devices to Korean hospitals and nursing facilities while pursuing FDA certification and digital health platform expansion.

Ownership category

akta.pro rank

Product category

Urology medical devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Urinary Catheters & Drainage (Intermittent/Foley Catheters, Bags, Securement) (HLAHALAI)

akta.pro secondary industry

Urology Telemedicine Platforms (HLALAGAN)

Keywords

• Urology medical devices
• Automated bladder irrigation
• Catheter systems
• Infection prevention technology
• Digital health platform

Headquarters

HQ city

Kimhae

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. UroRinse™ Light Sales: Sale of automated bladder irrigation medical devices to hospitals, nursing facilities, and home care settings. The product received Korean medical device manufacturing certification on October 28, 2025. Plans to pursue FDA and CE certification for international sales.
2. Digital Health Platform Services: Future revenue stream from AI-powered infection prevention insights, remote monitoring services, and EMR integration through the connected digital health ecosystem.
3. UroAll® Solution Catheter Products: Sale of functional catheter systems for urology care, including drug-eluting catheters for urethral and bladder management.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

UMED Inc. develops and sells urology medical devices for hospitals, nursing facilities, and home care settings. Its flagship UroRinse™ Light is the world's first fully automated bladder irrigation system that uses multi-sensor technology and a closed-circuit design to standardize catheter flushing and reduce catheter-associated urinary tract infections. The company also offers the UroAll® Solution drug-eluting catheter system and is building a connected digital urology healthcare platform with mobile apps, cloud data, AI-powered medical information services, and EMR/IoMT integration.

Product overview

UMED Inc. offers a portfolio of urology medical devices and an AI-powered digital health platform. The core products are UroRinse™ Light, the world's first automated bladder irrigation system with sensor-based automation and closed-system design, and UroAll® Solution, a specialized functional catheter system. These devices are integrated into a broader digital urology platform that includes mobile apps, cloud databases, AI-powered medical information services with chatbot Q&A, and AI-driven symptom analysis for medical referrals and telemedicine connectivity. The platform aims to shift urology care from treatment-centered to prevention-centered paradigms.

Differentiator

Problem solved

Functional benefit

Brands

• UroRinse™ Light: World's first automated bladder irrigation system - a smart medical device for automated and standardized bladder irrigation to reduce catheter-associated urinary tract infections.
• UroAll® Solution

Products and services

• UroRinse™ Light World's first fully automated bladder irrigation system that uses sensor-based automation and a closed-circuit design to standardize catheter flushing for hospitals, nursing facilities, and home care settings, targeting catheter-associated urinary tract infection (CAUTI) prevention.
• UroAll® Solution Functional drug-eluting catheter system specialized for urethral and bladder management, designed to improve patient quality of life and clinical utility for urology patients.

Quantifiable outcome

• CAUTI prevention effectiveness validated through preclinical study published in Urology journal (Gold Journal)
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• People & Technology (피플앤드테크놀러지)coreTechnology or Integration · 20 August 2025Strategic MOU for urology medical IoMT cooperation. Jointly developing smart medical service platform that integrates UMED's urology smart devices with hospital information systems by 2027. People & Technology's IndoorPlus+ SmartCare platform (BLE-based sensors for patient/medical device location and vital data monitoring) will connect with UMED devices, enabling real-time procedure data viewing by medical staff and smart clinical environment.
• BioPlus (바이오플러스)minorStrategic or Co-development Partner · 26 October 2021MOU for joint research on urethral stricture medical devices. Development of drug-eluting catheter and anti-adhesion agent (Interblock) for urethral reconstruction. BioPlus provides anti-adhesion technology for urology application expansion.
• Asan Medical Center (서울아산병원)coreStrategic or Co-development PartnerMajor Korean hospital partner for clinical trials and product validation of UroRinse™ Light automated bladder irrigation system.
• Seoul National University Hospital (SNUH, 서울대학교병원)coreStrategic or Co-development PartnerPartner hospital for clinical trials and product development of urology medical devices.
• Ulsan University Hospital (울산대학교병원)coreStrategic or Co-development PartnerPartner hospital for clinical trials and product development, also supporting company's Ulsan expansion plans.
• University of California San Diego (UCSD)coreStrategic or Co-development PartnerJoint research partner for preclinical studies of UroRinse™. Collaborative study published in Urology journal demonstrated effectiveness in CAUTI prevention. Led by Professor Mahadevan Raj Rajasekaran.
• BTV Ventures (비티비벤처스)coreStrategic or Co-development PartnerOperating partner for Gyeongnam Startup Accelerating program (2023-2025). Provided 3 billion KRW in direct investment to program participants including UMED, organized global expansion programs including Singapore roadshow to SWITCH exhibition, and facilitated connections with ATUM Ventures, A*STAR, NUS, NTU, Infineon.
• Samsung Heavy Industries (삼성중공업)minorStrategic or Co-development PartnerCorporate collaboration through 2024 Startup Growth Package program. UMED presented collaboration achievements with Samsung Heavy Industries during program成果 sharing event.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Convatec: Global medical products company with continence care and ostomy franchises including catheter-based products. Comparable as a broad incumbent addressing catheterized patient care.
• Hollister Incorporated: US-based manufacturer of ostomy, continence, and critical care products including urinary drainage catheters. Comparable as a competing medical-device incumbent serving the same hospital and home-care urology/continence customers.
• Coloplast: Danish global leader in ostomy, continence, and wound care, including a substantial urology catheter portfolio. Directly comparable as a competitor in urinary catheters and bladder management devices that UMED addresses via UroRinse Light and UroAll.
• Becton, Dickinson and Company (BD): Global medical technology company with a substantial urology and infection-prevention portfolio. Comparable as a large incumbent that could enter automated bladder irrigation or supply competing catheter-based systems.
• Cook Medical: US-based privately held medical device company with a urology division offering catheter, stent, and drainage products. Comparable as a broad medical-device incumbent with overlapping urology product lines.
• B. Braun: Global medical and pharmaceutical device company with a urology and continence care portfolio including catheter systems. Comparable as a large multi-category medical-device competitor serving the same hospital customer base.

Direct peers

• Teleflex Incorporated: Medical device company with a focused urology franchise (e.g., Rusch, Urocare) including urinary catheters and drainage products. Most directly comparable as a catheter and urology-device specialist competing for the same clinical customers.
• WellSPECT Healthcare (formerly Astra Tech): Specialist urology and continence care company (LoFric catheters, Navina) acquired by Investor AB. Comparable as a focused direct peer in catheter and bladder-management products with strong clinical evidence positioning similar to UMED's.

Emerging players

• UroGen Pharma: Specialty urology company developing drug-delivery and therapeutic solutions for urologic conditions, including drug-eluting technologies for bladder and urothelial disease. Comparable as an emerging specialist with overlapping drug-eluting catheter/urology focus similar to UMED's UroAll.
• Calyxo (and other catheter-disruption startups): Venture-backed medical device company developing catheter-based technologies for urological conditions such as kidney stones. Comparable as an emerging player attacking legacy catheter-based urology workflows with novel device approaches, similar to UMED's automation thesis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UMED Inc.